Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-1101 (Idelalisib) in Previously Treated CLL
NCT01659047Phase 2Withdrawn
- Sponsor
- Gilead Sciences
- Start
- Aug 2012
- Primary completion
- Dec 2014
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of idelalisib in chronic lymphocytic leukemia (CLL), sponsored by Gilead Sciences. Planned start Aug 2012; status: withdrawn.
02
Drugs
idelalisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01659047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01659047.